CLEVELAND, Oct. 31 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(Boston Stock Exchange:CFB), today announced that the Company is scheduled to present at the Rodman & Renshaw 8th Annual Global Healthcare Conference, on November 6-8, in New York City.

Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, will give a presentation on the Company followed by a question and answer session on November 7, at 3:30 p.m. ET.

A live webcast of Cleveland BioLabs' presentation can be accessed at the Company's website, or at A replay of the presentation will be archived for 90 days after the conference, at the same locations. For more information about the Rodman & Renshaw 8th Annual Healthcare Conference, please visit Rodman & Renshaw's website

Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is a small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis (programmed cell death). The Company has received approval to initiate Phase II trials with CBLC102 in hormone refractory prostate cancer.

The Company's other lead compound, CBLB502, is a modified protein of a microbe that protects cells from apoptosis. It has shown efficacy in protection against lethal doses of radiation in rodents and non-human primates and is on an accelerated approval pathway for the treatment of acute radiation syndrome, which results from exposure to high levels of radiation following a nuclear or radiological incident. Other applications for this technology include protection from cancer treatment side effects.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors."

     The Global Consulting Group
     Rachel Levine
     T: (646) 284-9439